Abstract: Breast cancer studies presented at the 2022 ASCO meeting demonstrated several novel findings: improved survival prognosis in patients with low HER-2 expression with HER-2-targeted therapy, prolonged progression-free survival (PFS) with sacituzumab govitecan in patients with HR-positive/HER-2-negative metastatic breast cancer, oncodriver gene HER-3 as a new target for breast cancer treatment, negative overall survival outcomes with palbociclib combined with letrozole as the first-line treatment, hormone replacement therapy, and further improvement in PFS with continued CDK4/6 inhibitor therapy after progression of standard therapy in HR-positive/HER-2-negative metastatic breast cancer. This article reviews important advances in the treatment of metastatic breast cancer from this conference.